Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2023 08:25 ET | Source: Arch Biopartners

Grant of Options to Directors and Officers

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that its Board of Directors has granted a total of...
December 13, 2023 07:25 ET | Source: Arch Biopartners

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...
October 24, 2023 07:30 ET | Source: Arch Biopartners

Shares for Interest Debt Settlement

TORONTO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt...
September 22, 2023 07:00 ET | Source: Arch Biopartners

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of...
July 31, 2023 18:02 ET | Source: Arch Biopartners

Arch Biopartners Engages Independent Trading Group as Market Maker

TORONTO, July 31, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has engaged the services of Independent...
June 27, 2023 07:15 ET | Source: Arch Biopartners

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...
April 18, 2023 07:10 ET | Source: Arch Biopartners

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel...
March 23, 2023 07:00 ET | Source: Arch Biopartners

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel...
February 07, 2023 07:05 ET | Source: Arch Biopartners

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...
December 15, 2022 09:49 ET | Source: Arch Biopartners

Shares for Interest Debt Settlement; Grants Options

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt...